Application of Tirofiban for percutaneous coronary intervention in patients with acute myocardial infarction

Objective: To evaluate the clinical value of Tirofiban for percutaneous coronary intervention(PCI) in patients with acute myocardial infarction(AMI).Methods: A total of 68 AMI patients were randomly divided into Tirofiban group(n=28),and control group(n=40).All the individuals were performed PCI within 12 hours after onset of AMI.All the individuals were given oral bolus dose of Clopidogrel 300~600 mg,Aspirin 300 mg before PCI and Clopidogrel 75 mg per day,Aspirin 75 mg per day after PCI.All the individuals were intravenous administered heparin 8 000~10 000 U during PCI.All the Tirofiban group were injected Tirofiban(10 μg·kg-1) into artery(IRA) during PCI and intravenously administered Tirofiban 24~36 hours(0.15 μg·kg-1·min-1) after PCI.The coronary TIMI flow of IRA after PCI,major adverse cardiac events(MACE) rates within 30 days,bleeding complications were analyzed and between the two groups. Results: Three degree TIMI myocardial perfusion of Tirofiban group was 96.4%(27/28),but control group was 82.5%(33/40)(P0.05).The MACE rate of Tirofiban group was 7.1%(2/28),but control group was 17.5%(7/40)(P0.05).There were no difference of complication of bleeding between the two groups(P0.05). Conclusion: Application of Tirofiban intracoronary injection during primary PCI in patients with AMI was safe and effective,which may reduce the occurrence of MACE,and improve TIMI flow of IRA in patients with AMI during primary PCI.